None

Mobocertinib/Mobocertinib (Mobocertinib) is a targeted treatment for lung cancer and is a tyrosine kinase inhibitor. According to current research, mobosetinib has strong brain-blood barrier permeability and can cross the blood-brain barrier and enter the central nervous system. A clinical study showed that mobosertinib showed limited intracranial activity in patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer and brain metastases.

The brain-blood barrier is a tight physiological barrier between blood and brain tissue that protects the brain from external substances. However, some drugs may need to work within the brain and therefore need to be able to cross the brain-blood barrier. Mobosetinib exerts its therapeutic effects by binding to and inhibiting specific tyrosine kinases in the brain, making it sufficiently permeable to cross the blood-brain barrier. The permeability of the brain-blood barrier to different drugs may vary and needs to be evaluated based on the characteristics and dosage of the drug.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.